Alnylam Pharmaceuticals
ALNY
ALNY
401 hedge funds and large institutions have $21B invested in Alnylam Pharmaceuticals in 2021 Q3 according to their latest regulatory filings, with 48 funds opening new positions, 154 increasing their positions, 120 reducing their positions, and 41 closing their positions.
New
Increased
Maintained
Reduced
Closed
Holders
401
Holders Change
+3
Holders Change %
+0.75%
% of All Funds
7.04%
Holding in Top 10
9
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.16%
New
48
Increased
154
Reduced
120
Closed
41
Calls
$275M
Puts
$138M
Net Calls
+$136M
Net Calls Change
+$120M
Top Buyers
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
$1.11B |
| 2 |
Lord, Abbett & Co
Jersey City,
New Jersey
|
$52.9M |
| 3 |
APM
Avidity Partners Management
Dallas,
Texas
|
$80.6M |
| 4 |
BlackRock
New York
|
$1.68B |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
$3.37B |
Top Sellers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
$1.39B |
| 2 |
MC
Maverick Capital
Dallas,
Texas
|
$752K |
| 3 |
Alkeon Capital Management
New York
|
$73.7M |
| 4 |
ACA
Avoro Capital Advisors
New York
|
$160M |
| 5 |
JPMorgan Chase & Co
New York
|
$462M |
